Cargando…
Biomarkers for immunotherapy in bladder cancer: a moving target
Treatment options for metastatic urothelial carcinoma (mUC) remained relative unchanged over the last 30 years with combination chemotherapy as the mainstay of treatment. Within the last year the landscape for mUC has seismically shifted following the approval of five therapies targeting the program...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697433/ https://www.ncbi.nlm.nih.gov/pubmed/29157296 http://dx.doi.org/10.1186/s40425-017-0299-1 |